TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs
-I-Mab’s Broad and Innovative Pipeline to Leverage TRACON’s U.S. Product Development Solution Platform SHANGHAI, Nov. 29, 2018 /PRNewswire/ — TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on…